Allovir

ALVR

Current ValuationThe current P/E ratio is -0.84, within the reasonable range, cheaper than 55.72% of the time in the past 5 years, and the industry ranks 230/602, the industry Median -2.11.

-0.837xP/E
Stock price--

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-55.35x148.77%$179.33B
MRNAUSModerna
-25.75x15.53%$81.13B
NTRAUSNatera
-318.97x6.91%$61.35B
CSLLYUSCSL Limited
-22.97x--$59.23B
RVMDUSRevolution Medicines
-25.17x62.30%$44.51B
ROIVUSRoivant Sciences
-97.07x146.49%$25.84B
BNTXUSBioNTech SE
-12.53x17.09%$24.53B
INSMUSInsmed
-25.90x74.61%$22.67B
SMMTUSSummit Therapeutics
-16.09x19.55%$13.78B
TWSTUSTwist Bioscience
-98.71x20.00%$13.50B
BBIOUSBridgebio Pharma
-18.69x28.48%$12.93B
MDGLUSMadrigal Pharma
-35.08x51.06%$11.40B
IBRXUSImmunityBio
-11.09x151.32%$11.00B
PCVXUSVaxcyte
-10.32x54.35%$10.98B
KYMRUSKymera Therapeutics
-30.49x4.94%$9.13B
ARWRUSArrowHead Pharma
-27.53x36,308.30%$8.81B
CYTKUSCytokinetics
-9.75x6.37%$8.72B
SYREUSSpyre Therapeutics
-54.43x46.89%$8.18B
ABVXUSAbivax SA
-17.17x22.49%$8.00B
PRAXUSPraxis Precision Medicines
-23.35x3.05%$7.92B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.